We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+17.74%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$163M
AUM Growth
-$69.7M
Cap. Flow
-$67.5M
Cap. Flow %
-41.51%
Top 10 Hldgs %
62.79%
Holding
55
New
8
Increased
9
Reduced
9
Closed
21

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$6.42M
2
TERN
Terns Pharmaceuticals
TERN
+$4.99M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$4.79M
4
CBAY
Cymabay Therapeutics
CBAY
+$3.86M
5
KROS icon
Keros Therapeutics
KROS
+$3.74M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$17.8M
2
RLMD icon
Relmada Therapeutics
RLMD
+$13.5M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$9.84M
4
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
+$8.45M
5
BLU
BELLUS Health Inc.
BLU
+$7.52M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
51
DELISTED
Immunogen Inc
IMGN
– –
-140,000
Closed -$669K
MRTX
52
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-104,800
Closed -$7.32M
DICE
53
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-6,700
Closed -$136K
JYAC
54
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
– –
-562,500
Closed -$5.61M
BLSA
55
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
– –
-843,122
Closed -$8.45M
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Acuta Capital Partners held 55 positions worth $163M, down 30% from $232M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Acuta Capital Partners withdrew a net $67.5M in Q4 2022, closing 21 positions and reducing 9 holdings. Its most notable exit was Relmada Therapeutics, an estimated $13.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Mersana Therapeutics worth $5.57M.

  • Acuta Capital Partners's largest Q4 2022 buy was Mersana Therapeutics: 38,000 shares worth $5.57M.
  • Acuta Capital Partners added most to Terns Pharmaceuticals in Q4 2022, an estimated $4.99M increase.
  • Acuta Capital Partners's biggest Q4 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $17.8M.
  • Acuta Capital Partners fully exited Relmada Therapeutics in Q4 2022, selling an estimated $13.5M.
  • Acuta Capital Partners's ten largest holdings make up 63% of its $163M portfolio in Q4 2022.
  • Acuta Capital Partners opened 8 new positions and closed 21 in Q4 2022.
  • Acuta Capital Partners's portfolio value fell 30% quarter-over-quarter to $163M.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.